The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 28, 2023

Filed:

Feb. 07, 2018
Applicant:

Modalis Therapeutics Corporation, Chuo-ku, JP;

Inventors:

Tetsuya Yamagata, Cambridge, MA (US);

Yuanbo Qin, Cambridge, MA (US);

Haruhiko Morita, Cambridge, MA (US);

Talha Akbulut, Cambridge, MA (US);

Iain Robert Thompson, Cambridge, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/90 (2006.01); A61P 35/00 (2006.01); A61K 31/7105 (2006.01); C12N 15/113 (2010.01); C12N 15/86 (2006.01); C12N 15/11 (2006.01); C12N 9/22 (2006.01);
U.S. Cl.
CPC ...
C12N 15/907 (2013.01); A61K 31/7105 (2013.01); A61P 35/00 (2018.01); C12N 9/22 (2013.01); C12N 15/111 (2013.01); C12N 15/1135 (2013.01); C12N 15/86 (2013.01); C12N 2310/20 (2017.05); C12N 2740/16043 (2013.01);
Abstract

The present invention provides a method of treating a disease associated with elevated KRAS activity or expression in a subject, comprising suppressing KRAS expression in the subject by targeting an expression regulatory region of KRAS gene using a CRISPR-Guide Nucleotide Directed Modulation (GNDM). Also, provided is a CRISPR-GNDM system for suppressing KRAS expression comprising (a) a protein selected from the group consisting of dCas9 or dCpf1, a fusion protein of dCas9 or dCpf1 and Kruppel associated box (KRAB), and (b) a guide nucleotide targeting an expression regulatory region of KRAS gene.


Find Patent Forward Citations

Loading…